Product image of Jivolar (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Jivolar

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Jivolar (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a Biguanide/DPP-4 inhibitor combination presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH India supplies Jivolar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medochemie Hellas Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jivolar is indicated for the management of type 2 diabetes mellitus and related glycemic abnormalities.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Inadequate glycemic control with metformin alone: provides additional glucose reduction when combined with metformin.
  • High HbA1c levels: helps achieve target HbA1c in patients not meeting goals with monotherapy.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that promote glucose‑dependent insulin secretion and suppress glucagon release, together improving overall glycemic control.

Side Effects

Jivolar may cause a range of adverse reactions.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.
  • Diarrhea: loose stools occurring especially during treatment initiation.
  • Headache: mild to moderate intensity.
  • Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycemia: particularly when used with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Precautions & Warnings

Before prescribing Jivolar, clinicians should consider several safety factors.

  • Renal function: assess renal impairment as metformin accumulation can occur.
  • Hepatic function: monitor liver enzymes due to potential hepatic effects.
  • Cardiovascular disease: use cautiously in patients with heart failure.
  • Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection.
  • Pregnancy and lactation: safety not established; weigh benefits against risks.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Jivolar can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate renal dysfunction and metformin accumulation.
  • Insulin or sulfonylureas: increase risk of severe hypoglycemia.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may affect glucose control.
  • Corticosteroids: can elevate blood glucose requiring dose adjustments.
  • NSAIDs: may impair renal function, influencing metformin clearance.

Frequently Asked Questions

Jivolar is prescribed for the treatment of type 2 diabetes mellitus. It combines metformin, which improves insulin sensitivity, with sitagliptin, which enhances insulin secretion in response to meals, helping patients achieve better blood‑glucose control.

Metformin decreases hepatic glucose production and increases peripheral insulin sensitivity, while sitagliptin blocks the enzyme DPP‑4, raising levels of incretin hormones that stimulate glucose‑dependent insulin release and suppress glucagon. Together they provide complementary mechanisms to lower blood sugar.

The specific dose of Jivolar is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Jivolar in pregnancy and lactation are limited. Healthcare providers must weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women, and alternative treatments may be considered.

To request Jivolar, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jivolar offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitizing and incretin‑based actions in one tablet. This can simplify regimens compared with separate prescriptions of metformin and a DPP‑4 inhibitor, potentially improving adherence while delivering comparable glycemic efficacy.

Jivolar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children.

Jivolar is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycemia when used with insulin or sulfonylureas. Patients should be monitored for signs of these events and seek immediate medical attention if they occur.

Jivolar is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT